A new approach tested in Egypt could become the blueprint for providing cutting-edge medicines to the poor
Abdel Gawad Ellabbad knows exactly how he was infected with hepatitis C.
As a schoolboy in this Nile Delta rice-farming village, his class marched to the local clinic every month for injections against schistosomiasis, a parasitic disease spread by water snails.
A nurse would boil the syringes, fill each with five doses and then jab five boys in a row with a single needle.
“I didn’t want that hot needle touching me, so I thought I’d be smart,” Mr. Ellabbad, 52, said. “I let the other guys go first.”
Six million Egyptians were infected with hepatitis C by unsterile needles during the country’s decades-long fight against schistosomiasis. The virus spread insidiously; today, at least 10 percent of Egyptians, nearly nine million people, are chronically infected, the highest rate in the world.
But a grand experiment unfolding across the country may change all that.
Once demonized for withholding lifesaving AIDS drugs from poor countries in Africa, chastened pharmaceutical companies are testing an alternative strategy: a complicated deal to sell hepatitis drugs at a fraction of their usual cost while imposing tight restrictions intended to protect lucrative markets in the West.
The strategy has raised howls of outrage from public health advocates in some quarters. If it succeeds, though, the arrangement in Egypt may serve as a blueprint not just for curing hepatitis around the world, but also for providing other cutting-edge medicines to citizens in poor countries who could never afford them.
The experiment here is about a year old and, while still fragile, appears to be headed for success.
Mr. Ellabbad, for one, was finally cured of hepatitis this spring. An air-conditioning repairman, he took a three-month regimen that included sofosbuvir, first of the new generation of miracle drugs. The pills would have cost more than $84,000 in the United States.
He got them free from the Egyptian government, which paid about $900.
“Before, I felt like I was dying,” he said. “Now I feel like I’ve never felt before. Like I’m 35 again.”
A Worldwide Problem
Hepatitis C is a global crisis: About 150 million people are chronically infected, four times as many as have H.I.V., and about 500,000 die each year of its complications, particularly cirrhosis and liver cancer.
The Latest on: Hepatitis C
via Google News
The Latest on: Hepatitis C
- Global Hepatitis Test Kits Market 2020 Top Industry Trend and Segments Analysis upto 2026on November 29, 2020 at 10:10 am
MarketsandResearch.biz has published the latest and most trending report entitled Global Hepatitis Test Kits Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 that collates ...
- Hepatitis C Drug Market 2020 Trends, Size, Growth Insight, Share, Emerging Technologies, Share, Competitive, Regional, And Global Forecast To 2026on November 26, 2020 at 4:31 pm
Nov (The Expresswire) -- Global"Hepatitis C Drug Market"(2020-2026) status and position of worldwide and key regions, with perspectives ...
- Almost 38,000 Africans examined under Egypt’s hepatitis C initiativeon November 25, 2020 at 4:00 pm
Egyptian laborers line up for an examination check-up for Hepatitis C, at a construction site in Egypt's new "administrative capital", some 40 kms east of Cairo. (AFP/File Photo) Short Url ...
- Many infants with hep C-positive moms not screened for HCVon November 25, 2020 at 10:22 am
(HealthDay)—Less than one-third of infants born to mothers with hepatitis C virus infection (HCV+) receive appropriate HCV follow-up testing, according to a study presented at The Liver Meeting, the ...
- WCM-Q researchers produce a WHO report on hepatitis C and a path for eliminating the diseaseon November 23, 2020 at 11:14 am
Researchers at Weill Cornell Medicine-Qatar (WCM-Q), in partnership with the World Health Organisation (WHO), have produced a comprehensive report on the hepatitis C virus epidemic ...
- Qatar- WCM-Q researchers' WHO report offers guidance on eliminating hepatitis Con November 23, 2020 at 6:11 am
Researchers at Weill Cornell Medicine-Qatar (WCM-Q), in partnership with the World Health Organization (WHO), have produced a comprehensive report on the hepatitis C virus epidemic in the Eastern ...
- WCM-Q researchers' WHO report offers guidance on eliminating hepatitis Con November 23, 2020 at 3:14 am
Researchers at Weill Cornell Medicine-Qatar (WCM-Q), in partnership with the World Health Organization (WHO), have produced a comprehensive report on the hepatitis C virus epidemic in the Eastern Medi ...
- WCM-Q Researchers Rroduce a WHO Report on Hepatitis C and a Path for Eliminating the Disease in the Eastern Mediterranean Regionon November 23, 2020 at 1:48 am
Researchers at Weill Cornell Medicine-Qatar have produced a comprehensive report on the hepatitis C virus epidemic in the Eastern Mediterranean region Researchers at Weill Cornell Medicine-Qatar ...
- Hepatitis C Drugs Market Size, Share 2020, Industry Growth, SWOT Analysis, Top Company Profile, Regional Revenueon November 20, 2020 at 9:17 am
Overview. The increased prevalence of factors in several regions has contributed to the rise in the hepatitis C drug market. The pharmaceuticals industry ...
- Hepatitis Therapeutics Market: Increase in Prevalence of Viral Hepatitis Drives Marketon November 20, 2020 at 1:58 am
Transparency Market Research (TMR) has published a new report titled ‘Hepatitis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the ...
via Bing News